Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 2/20 | 0.58 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.48 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.48 |
| ▸ | PRKG1 | Q13976 | 2/20 | 0.48 |
| ▸ | PRKACA | P17612 | 1/20 | 0.48 |
| ▸ | PRKACG | P22612 | 1/20 | 0.48 |
| ▸ | PRKACB | P22694 | 1/20 | 0.48 |
| ▸ | AKT1 | P31749 | 1/20 | 0.48 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.48 |
| ▸ | GRM5 | P41594 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.46 |
| ▸ | MLNR | O43193 | 1/20 | 0.45 |
| ▸ | WNT3A | P56704 | 2/20 | 0.44 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16495932 | 0.88 | HPGDS (0.64) | HPGDSGABRA5ROCK2PRKG1PRKACA | |
| SCHEMBL16495572 | 0.87 | GABRA5 (0.48) | HPGDSGABRA5ROCK2PRKG1PRKACA | |
| SCHEMBL16495421 | 0.86 | HPGDS (0.51) | HPGDSGABRA5ROCK2PRKG1PRKACA | |
| SCHEMBL16495759 | 0.86 | HPGDS (0.53) | HPGDSGABRA5ROCK2PRKG1PRKACA | |
| SCHEMBL16495527 | 0.85 | NPC1 (0.56) | GABRA5DGAT1ALDH1A1RAB9ABAZ2B | |
| SCHEMBL16496423 | 0.85 | HPGDS (0.49) | HPGDSGABRA5ROCK2PRKG1PRKACA | |
| SCHEMBL16495644 | 0.84 | HPGDS (0.51) | HPGDSGABRA5ROCK2PRKG1PRKACA | |
| SCHEMBL16495943 | 0.84 | HPGDS (0.51) | HPGDSGABRA5ROCK2PRKG1PRKACA | |
| SCHEMBL16495828 | 0.83 | HPGDS (0.52) | HPGDSGABRA5ROCK2PRKG1PRKACA | |
| SCHEMBL16495568 | 0.83 | HPGDS (0.60) | HPGDSGABRA5ROCK2PRKG1PRKACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110306597-A1 | Nicotinamide Derivatives | CRAWFORTH JAMES MICHAEL (GB) | 2011-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306597-A1 | Nicotinamide Derivatives | NNT, NAMPT, NQO1 | HPGDS 1073/4885GABRA5 1938/4885ROCK2 4683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.